IDO1 and muscle atrophy: Though none of the IDO-1 inhibitors have been tested in a GC-treated model directly, increasing muscle tryptophan and preventing KYN accumulation through IDO-1 inactivation may lead to positive outcomes in various cases of muscle atrophy, including GC-related muscle atrophy.